- Home
- GLPG vs SKWD Comparison
GLPG vs SKWD Comparison
Compare GLPG & SKWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- SKWD
- Stock Information
- Founded
- GLPG 1999
- SKWD 2007
- Country
- GLPG Belgium
- SKWD United States
- Employees
- GLPG N/A
- SKWD N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- SKWD Property-Casualty Insurers
- Sector
- GLPG Health Care
- SKWD Finance
- Exchange
- GLPG Nasdaq
- SKWD Nasdaq
- Market Cap
- GLPG 2.1B
- SKWD 2.3B
- IPO Year
- GLPG 2005
- SKWD 2023
- Fundamental
- Price
- GLPG $31.44
- SKWD $48.69
- Analyst Decision
- GLPG Sell
- SKWD Buy
- Analyst Count
- GLPG 4
- SKWD 11
- Target Price
- GLPG $25.33
- SKWD $63.00
- AVG Volume (30 Days)
- GLPG 345.0K
- SKWD 427.6K
- Earning Date
- GLPG 07-23-2025
- SKWD 07-30-2025
- Dividend Yield
- GLPG N/A
- SKWD N/A
- EPS Growth
- GLPG N/A
- SKWD 6.84
- EPS
- GLPG N/A
- SKWD 3.16
- Revenue
- GLPG $323,674,692.00
- SKWD $1,253,720,000.00
- Revenue This Year
- GLPG N/A
- SKWD $17.46
- Revenue Next Year
- GLPG N/A
- SKWD $11.77
- P/E Ratio
- GLPG N/A
- SKWD $15.47
- Revenue Growth
- GLPG 5.43
- SKWD 21.67
- 52 Week Low
- GLPG $22.36
- SKWD $37.79
- 52 Week High
- GLPG $33.86
- SKWD $65.05
- Technical
- Relative Strength Index (RSI)
- GLPG 47.00
- SKWD 40.93
- Support Level
- GLPG $31.39
- SKWD $47.37
- Resistance Level
- GLPG $32.43
- SKWD $50.32
- Average True Range (ATR)
- GLPG 0.77
- SKWD 1.13
- MACD
- GLPG -0.22
- SKWD 0.31
- Stochastic Oscillator
- GLPG 7.22
- SKWD 44.75
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.